Sylvant (Siltuximab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increased diagnosis of multicentric castleman disease, improved awareness of cytokine-driven disorders, expansion of specialty oncology and immunology centers, advances in monoclonal antibody development, growing clinical use of targeted biologics.

The growth in the forecast period can be attributed to increasing exploration of additional inflammatory indications, rising demand for precision immunotherapy solutions, advancements in biologic drug formulation, expansion of specialty clinic networks, improved global access to rare disease treatments. Major trends in the forecast period include increasing adoption of targeted il-6 inhibitor therapies, growing use in rare immunological disorders, expansion of monoclonal antibody treatment protocols, enhanced focus on inflammatory pathway modulation, improved patient outcome monitoring.

The increasing prevalence of multicentric Castleman disease (MCD) is expected to drive the growth of the Sylvant (siltuximab) market going forward. Multicentric Castleman disease (MCD) is a rare disorder characterized by abnormal enlargement of lymph nodes and tissues, often associated with immune system dysfunction and inflammation. The rising incidence of MCD is attributed to factors such as improved diagnostic techniques, greater awareness, and advances in medical imaging. Sylvant (siltuximab) works by inhibiting interleukin-6 (IL-6), a cytokine involved in inflammation and disease progression in MCD. By blocking IL-6, Sylvant helps control abnormal lymph node growth and reduces inflammation, offering an effective treatment option for patients. For instance, in February 2025, Consult QD reported that Sylvant, the only FDA-approved therapy for iMCD in the U.S., was used in only 22% of patients, highlighting a significant unmet treatment need. Therefore, the increasing prevalence of MCD is driving the growth of the Sylvant (siltuximab) market.

The growing emphasis on precision medicine is expected to propel the growth of the Sylvant (siltuximab) market. Precision medicine tailors healthcare treatments to individual genetic profiles, lifestyles, and environmental factors, enabling more effective and targeted therapies. The rising adoption of precision medicine is driven by advances in genetic research, increased focus on personalized care, and the development of targeted therapeutics. Sylvant (siltuximab) exemplifies this approach by specifically targeting elevated IL-6 levels in MCD patients, offering a more personalized and effective treatment compared to conventional therapies. For instance, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the focus on precision medicine is driving the growth of the Sylvant (siltuximab) market.

Major companies operating in the Sylvant (siltuximab) market are focusing on developing monoclonal antibody therapies to meet the rising demand for targeted treatments for multicentric Castleman disease (MCD). Monoclonal antibodies are engineered to bind specifically to disease-associated proteins, modulating immune responses and improving patient outcomes compared to traditional treatments. For instance, in September 2024, the European Commission approved Sylvant (siltuximab) as a treatment for MCD. Sylvant binds to interleukin-6 (IL-6), inhibiting its activity, reducing inflammation, and alleviating disease symptoms. This therapy provides a targeted, non-chemotherapy option for patients with MCD.

Major companies operating in the sylvant (siltuximab) market are Recordati Rare Diseases Inc.

North America was the largest region in the sylvant (siltuximab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sylvant (siltuximab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sylvant (siltuximab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the sylvant market by increasing costs of imported biologic manufacturing inputs, monoclonal antibody processing equipment, cold-chain transportation services, and regulatory-compliant packaging. North America and Europe are most affected due to dependence on international biologics supply chains, while other regions face higher import-related pricing. These tariffs elevate treatment costs and reimbursement pressure. At the same time, they are supporting regional biologics manufacturing expansion, localized production investments, and strengthened domestic capabilities for rare disease biologic therapies.

The sylvant (siltuximab) market research report is one of a series of new reports that provides sylvant (siltuximab) market statistics, including sylvant (siltuximab) industry global market size, regional shares, competitors with a sylvant (siltuximab) market share, detailed sylvant (siltuximab) market segments, market trends and opportunities, and any further data you may need to thrive in the sylvant (siltuximab) industry. This sylvant (siltuximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sylvant (siltuximab) is a monoclonal antibody that targets and neutralizes interleukin-6 (IL-6), a cytokine involved in inflammation and immune responses. By inhibiting IL-6, it helps reduce inflammation, regulate immune activity, and manage symptoms in conditions such as multicentric Castleman’s disease (MCD). It is used to improve quality of life and slow disease progression in affected patients.

The primary indications for Sylvant include multicentric Castleman’s disease (MCD), HIV-associated multicentric Castleman’s disease (MCD), and non-Hodgkin lymphoma (NHL). Multicentric Castleman’s disease is a rare immune disorder characterized by abnormal lymphoid tissue growth, and Sylvant works by targeting specific proteins to reduce inflammation and improve outcomes. The medication is available in various formulations, including injections, vials, lyophilized powder, solutions for infusion, and prefilled syringes, and is used in hospitals, specialty clinics, ambulatory surgical centers (ASCs), and home care settings.

The sylvant (siltuximab) market consists of sales of oral dosage forms, compounded solutions, and intravenous (IV) infusion bags. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.